Karyopharm Therapeutics | KPTI - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 538M 2026-03
Abbott USD 9.31B 104M 2026-03
Amgen USD 4.78B 1.12B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Incyte USD 5.62B 4.5B 2026-03
J&J USD 17.44B 1.53B 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
MacroGenics USD 21.2M 32.13M 2026-03
Merck USD 18.17B 8.01B 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Novartis USD 9.29B 507M 2026-03
Novartis USD 9.8B 23M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Takeda JPY 1.11T 85.29B 2026-03
Tectonic Therapeutic USD 21.52M 374K 2025-12
TG Therapeutics USD 170.12M 28.04M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Xencor USD 82.38M 513K 2026-03